Digistain · Oct 2025
Digistain launched its first international laboratory in South Africa with OriGenes and UVU Africa, and the post also highlights the company’s 2025 EIT Health Open Innovation Breast Cancer Challenge win.
Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow
Company research
Public company, workplace, funding, and market signals
Overview
UK medtech/biotech company building an MHRA-cleared, UKCA-marked AI-enabled breast-cancer recurrence-risk platform that analyzes routine FFPE tissue with infrared spectrometry and quantitative histopathology to support treatment decisions and reduce unnecessary chemotherapy.
Primary product
Digistain Test / AI-enabled quantitative histopathology breast-cancer recurrence-risk platform
Founded
2019
Headquarters
Newport Pagnell, Buckinghamshire, United Kingdom
Team size
10-20 employees
Industry
Biotechnology Research
Sub-industry
AI-enabled breast cancer diagnostics / biomarker analytics
Offices
Newport Pagnell, Buckinghamshire, United Kingdom
London, United Kingdom
Business model
B2B clinical diagnostics
B2B2C insurer-reimbursed testing
hospital and lab deployments
clinical validation and research partnerships
Funding
Stage
Seed / bridge
Total raised
$1.2M
Latest round
Unattributed VC / bridge round · Jun 2025
People & investors
Leadership
Chief Executive Officer / Founder / Scientific Lead
Chief Operating Officer
Co-founder / Director
Chief Technology Officer
Non-Executive Director
Work & culture
Mission-driven, clinically focused, evidence-led, and internationally collaborative; the public-facing culture emphasizes equitable access to breast-cancer diagnostics, research validation, and partnerships with hospitals, insurers, and academic groups.
Product & market
Pricing
Per-test, provider- and insurer-reimbursed diagnostic service; public list pricing is not disclosed.
Differentiators
- —MHRA-cleared and UKCA-marked
- —Uses protein-level / downstream analysis rather than genomic testing
- —Analyzes routine FFPE tissue without molecular extraction
- —Fast turnaround versus multi-week genomic tests
- —Lower-cost alternative to traditional molecular profiling
- —Designed to fit into existing histopathology workflows
Technology
infrared spectrometry
optical scan technology
protein-level biomarker analytics
multivariate AI model
FFPE tissue section analysis
workflow-integrated digital pathology
cloud data systems and automation
GDPR-compliant operational tooling
Customers
Bupa
WPA Health Insurance
Healix
UK NHS Trusts
Hospital 12 de Octubre
Competitors
Agendia
Myriad Genetics
OncoStem
ArteraAI
ScreenPoint
AIdoc
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
1.8K
Traffic estimate as of Oct 2025
Latest news
Digistain · Sep 2025
Digistain said it won the challenge from EIT Health, AstraZeneca Spain, SERMAS, and Hospital 12 de Octubre, with Spain rollout starting at Hospital 12 de Octubre.
Innovate UK Business Connect · Jan 2025
Case study says Digistain received a £350,000 Innovate UK Smart Grant, a £10,000 RTO/Catapult grant, and later secured £400,000 in private investment to accelerate growth.
Digistain · Dec 2024
Deloitte selected Digistain as one of its top 5 most innovative companies out of nearly 300 startups in its Health & BioTech Accelerator programme.
Digistain · Nov 2024
Digistain announced reimbursement availability through Bupa, WPA Health Insurance, and Healix for over 60% of UK private patients.
Jobs and careers at Digistain
0 jobs at Digistain
No open positions
Check back later for new openings